H.C. Wainwright Reaffirms Buy Rating for Scilex Holding Co.
Recently, H.C. Wainwright maintained its Buy rating on Scilex Holding Co. (NASDAQ: SCLX) shares and set a steadfast price target of $7.00. The analyst has noted the company's recent financial strategies, notably closing a successful registered direct offering earlier this month. This offering raised $50 million through senior secured convertible notes, also granting warrants to purchase up to 7.5 million shares of Scilex's common stock.
Details of the Convertible Notes Offering
The convertible notes carry an original issue discount of 10% alongside an annual interest rate of 5.5%. These notes are scheduled to mature in two years unless converted or redeemed earlier. Scilex effectively garnered $22.5 million in cash from 3i LP and Murchinson affiliates, excluding fees and expenses associated with this offering.
In an intriguing development, Scilex has also entered into an agreement with Oramed Pharmaceuticals (NASDAQ: ORMP), which maintains a Neutral rating. This exchange involves reducing the principal balance of an existing senior secured promissory note by $22.5 million.
Impact of the Offering on Scilex's Financial Strategy
The tranche B senior secured convertible notes allow conversions into Scilex common stock at any time, either fully or partially, at a conversion price of $1.09 per share, subject to certain adjustments. The warrants tied to these notes can be exercised at the same conversion price and will be valid for five years post-issuance.
Scilex plans to deploy the funds from this offering—approximately $20.5 million after deductions—across various essential needs, including repaying $12.5 million of the Oramed note, settling a revolving credit facility with eCapital Healthcare Corp, covering related costs and fees, and supporting overall corporate operations.
Future Prospects of Scilex Pharmaceuticals
Looking forward, Scilex Holding Company is exploring several strategic avenues to enhance shareholder value, especially concerning its subsidiary, Scilex Pharmaceuticals. These options may entail a possible spinoff or public listing that could heighten Scilex Pharma's perceived worth, particularly in light of its recent expansions and FDA-approved products.
Notably, ZTlido has demonstrated impressive sales figures, boasting an approximate 50% rise in gross sales over the past two years, with expectations to surpass $180 million in sales for this year.
Growth in Non-Opioid Pain Management Products
During the most recent quarter, Scilex reported substantial growth in the net sales of its non-opioid pain management offerings, with ZTlido's sales estimated between $11.0 million and $13.0 million. The company has also successfully acquired a $50 million convertible note offering involving strategic partners to refinance existing debts and further solidify long-term growth.
Recent Developments and Regulatory Approvals
In other recent news, Scilex Holding Company has extended its payment deadline regarding its agreement with Oramed Pharmaceuticals and has satisfied a $10 million loan commitment through product delivery to FSF 33433 LLC.
The U.S. Food and Drug Administration has also approved revisions to the labeling of GLOPERBA®, a gout treatment, to ensure precision dosing, elevating Scilex's regulatory stance. Furthermore, the company has achieved Drug Distributor Accreditation from the National Association of Boards of Pharmacy, adding to its credibility.
Market Performance Insights
Recent insights into Scilex Holding Co.'s financial performance reveal a company actively managing its market presence despite ongoing challenges. Although Scilex is currently unprofitable, its financial maneuvers may yield positive results in the future. The outlook from H.C. Wainwright underscores this confidence, illustrating the firm’s steadfast rating amidst fluctuating market conditions.
Scilex has shown notable revenue growth, with quarterly revenues increasing by over 30%, positively impacting investor sentiment and reinforcing H.C. Wainwright's Buy rating.
Frequently Asked Questions
What is the recent rating for Scilex Holding Co.?
H.C. Wainwright has reaffirmed its Buy rating for Scilex shares with a price target of $7.00.
How much capital did Scilex raise from its recent offering?
Scilex raised $50 million through a registered direct offering of senior secured convertible notes.
What are the key products sold by Scilex?
Key products include ZTlido, a topical non-opioid treatment for pain management.
What strategic options is Scilex considering for its subsidiary?
Scilex is considering a possible spinoff or public listing for Scilex Pharmaceuticals to maximize shareholder value.
What recent approvals has Scilex received from the FDA?
Scilex received FDA approval for labeling updates on GLOPERBA® to enhance precision dosing.
